All Stories

  1. 改善精神疾病患者之安樂死管控:從比利時看安樂死的刑事法院判決(二)
  2. 比利時案例認定為精神疾病患者安樂死並不違反歐洲人權公約
  3. Evaluating Monitoring Guidelines of Clozapine-Induced Adverse Effects: a Systematic Review
  4. Euthanasia for unbearable suffering caused by a psychiatric disorder: improving the regulatory framework
  5. E-book: Ethiek en gezondheidsrecht - Uitgave 2023
  6. Associations between childhood adversity, psychiatric symptoms, and self‐esteem outcomes in adolescents and young adults: An experience sampling study
  7. Gender differences in the associations between childhood adversity and psychopathology in the general population
  8. Viewpoint: Psychiatrists and other medical professionals in Belgium show a substantial lack of knowledge about poverty
  9. The within-person bidirectional association between physical activity and loneliness in the daily lives of adolescents and young adults
  10. Differential associations of childhood adversity subtypes and psychopathology in men and women
  11. Sustainability in Dutch and Flemish mental healthcare: A descriptive and comparative study
  12. Affective wellbeing moderates the association between polygenic risk score for neuroticism and change in neuroticism
  13. De Belgische Euthanasiewet doorstaat de mensenrechtelijke toets, behalve voor de a posteriori-controle (Mortier tegen België (nr. 78017/17))
  14. Coping and sleep quality in youth: An Experience Sampling study
  15. Media coverage of Belgium’s first criminal case concerning euthanasia for psychiatric patients: A content analysis of Flemish newspapers and magazines
  16. New Directions in the Ethics of Assisted Suicide and Euthanasia
  17. The Belgian euthanasia law under scrutiny of the highest courts
  18. Due Care in the Context of Euthanasia Requests by Persons with Psychiatric Illness: Lessons from a Recent Criminal Trial in Belgium
  19. Gene–environment interaction study on the polygenic risk score for neuroticism, childhood adversity, and parental bonding
  20. Prevalence and characteristics of registered falls in a Belgian University Psychiatric Hospital
  21. Klassieke psychedelica als behandeling voor depressie: waar staan we vandaag?
  22. The relationship between daily positive future thinking and past-week suicidal ideation in youth: An experience sampling study
  23. Falls Among Psychiatric Inpatients: A Systematic Review of Literature
  24. Severe Mental Illness and Cardiovascular Disease
  25. Improving control over euthanasia of persons with psychiatric illness: Lessons from the first Belgian criminal court case concerning euthanasia
  26. General psychopathology and its social correlates in the daily lives of youth
  27. Correction to: 49th ESCP virtual symposium on clinical pharmacy 19.10.2021–21.10.2021 Clinical pharmacy, working collaboratively in mental health care
  28. The relationship between daily positive future thinking and past-week suicidal ideation in youth: An experience sampling study
  29. Be(com)ing social: Daily-life social interactions and parental bonding.
  30. Barriers to Somatic Health Care for Persons With Severe Mental Illness in Belgium: A Qualitative Study of Patients' and Healthcare Professionals' Perspectives
  31. COVID-19-Related Mortality Risk in People With Severe Mental Illness: A Systematic and Critical Review
  32. Depression and post-traumatic stress disorder after perinatal loss in fathers: A systematic review
  33. Euthanasia of a person with a psychiatric disorder does not violate the European Convention on Human Rights (Mortier v. Belgium [no. 78017/17])
  34. COVID-19 Vaccination Rates in a Cohort Study of Patients With Mental Illness in Residential and Community Care
  35. Momentary Manifestations of Negative Symptoms as Predictors of Clinical Outcomes in People at High Risk for Psychosis: Experience Sampling Study
  36. COVID-19 vaccine uptake in patients with psychiatric disorders admitted to or residing in a university psychiatric hospital
  37. The complex and dynamic interplay between self-esteem, belongingness and physical activity in daily life: An experience sampling study in adolescence and young adulthood
  38. Major depressive disorder: a possible typisation according to serotonin, inflammation, and metabolic syndrome
  39. Emotion regulation in response to daily negative and positive events in youth: The role of event intensity and psychopathology
  40. Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study
  41. The Role of Working Memory in the Processing of Scalar Implicatures of Patients With Schizophrenia Spectrum and Other Psychotic Disorders
  42. COVID-19 vaccination for people with severe mental illness: why, what, and how?
  43. Network dynamics of momentary affect states and future course of psychopathology in adolescents
  44. Model-based PID-5 domain clusters and levels of impairment in self and interpersonal functioning
  45. The search for an autoimmune origin of psychotic disorders: Prevalence of autoantibodies against hippocampus antigens, glutamic acid decarboxylase and nuclear antigens
  46. The clinical characterization of the patient with primary psychosis aimed at personalization of management
  47. The Impact of Pharmacological and Non-Pharmacological Interventions to Improve Physical Health Outcomes in People With Schizophrenia: A Meta-Review of Meta-Analyses of Randomized Controlled Trials
  48. Stress reactivity as a putative mechanism linking childhood trauma with clinical outcomes in individuals at ultra-high-risk for psychosis: Findings from the EU-GEI High Risk Study
  49. Defining polypharmacy: in search of a more comprehensive determination method applied in a tertiary psychiatric hospital
  50. Identification and management of cardiometabolic risk in subjects with schizophrenia spectrum disorders: A Delphi expert consensus study
  51. Risk of Hospitalized Falls and Hip Fractures in 22,103 Older Adults Receiving Mental Health Care vs 161,603 Controls: A Large Cohort Study
  52. Links between the amount of antipsychotic medication prescribed per population at general practice level, local demographic factors and medication selection
  53. Prioritizing COVID ‐19 vaccination for people with severe mental illness
  54. Early warning signals in psychopathology: what do they tell?
  55. Impact of Psychotropic Medication Effects on Obesity and the Metabolic Syndrome in People With Serious Mental Illness
  56. Physical activity participation is associated with higher quality of life scores in men with alcohol use disorders: a study from Uganda
  57. The clinical characterization of the adult patient with depression aimed at personalization of management
  58. General psychopathology and its social correlates in the daily lives of youth
  59. Lower emotional complexity as a prospective predictor of psychopathology in adolescents from the general population.
  60. Modeling psychological function in patients with schizophrenia with the PANSS: an international multi-center study
  61. Be(com)ing social: Daily-life social interactions and parental bonding
  62. Polygenic liability for schizophrenia and childhood adversity influences daily‐life emotion dysregulation and psychosis proneness
  63. Measuring resilience prospectively as the speed of affect recovery in daily life: a complex systems perspective on mental health
  64. Test-retest reliability, concurrent validity and correlates of the two-minute walk test in outpatients with psychosis
  65. TwinssCan — Gene-Environment Interaction in Psychotic and Depressive Intermediate Phenotypes: Risk and Protective Factors in a General Population Twin Sample
  66. Barriers, attitudes, confidence, and knowledge of nurses regarding metabolic health screening and intervention in people with mental illness: a pilot study from Uganda
  67. Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study
  68. The sublingual use of atropine in the treatment of clozapine‐induced sialorrhea: A systematic review
  69. Which clinical and biochemical predictors should be used to screen for diabetes in patients with serious mental illness receiving antipsychotic medication? A large observational study
  70. Reduced interhemispheric and increased intrahemispheric connectivity in schizophrenia brain networks
  71. A quantitative assessment of the views of mental health professionals on exercise for people with mental illness: perspectives from a low-resource setting
  72. Evidence for interaction between genetic liability and childhood trauma in the development of psychotic symptoms
  73. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis
  74. 7.3 POLYGENIC RISK FOR SCHIZOPHRENIA MODERATES THE INFLUENCE OF CHILDHOOD ADVERSITY ON DAILY-LIFE EMOTIONAL DYSREGULATION AND PSYCHOSIS PRONENESS
  75. Associations of the Built Environment With Physical Activity and Sedentary Time in Ugandan Outpatients With Mental Health Problems
  76. Health care professionals’ perspectives on physical activity within the Ugandan mental health care system
  77. Evidence that the association of childhood trauma with psychosis and related psychopathology is not explained by gene-environment correlation: A monozygotic twin differences approach
  78. Stratification and prediction of remission in first-episode psychosis patients: the OPTiMiSE cohort study
  79. The impact of pharmacological and non‐pharmacological interventions to improve physical health outcomes in people with schizophrenia: a meta‐review of meta‐analyses of randomized controlled trials
  80. Alpha7 acetylcholine receptor autoantibodies are rare in sera of patients diagnosed with schizophrenia or bipolar disorder
  81. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study
  82. The Urgent Need for Optimal Monitoring of Metabolic Adverse Effects in Children and Youngsters Who Take On-label or Off-label Antipsychotic Medication
  83. EPA guidance on physical activity as a treatment for severe mental illness: a meta-review of the evidence and Position Statement from the European Psychiatric Association (EPA), supported by the International Organization of Physical Therapists in Ment...
  84. Patients with psychosis struggle with scalar implicatures
  85. S182. Evidence That the Polygenic Risk Score for Neuroticism Does Not Moderate the Impact of Childhood Trauma on Neuroticism: A GxE Model
  86. O42. Gene-Environment Correlation Does not Explain Away the Association Between Childhood Trauma and Psychopathology: A Monozygotic Twin Differences Approach
  87. Exercise self-efficacy correlates in people with psychosis
  88. O4.4. DOES POLYGENIC RISK SCORE FOR SCHIZOPHRENIA MODERATE THE MOMENTARY AFFECTIVE AND PSYCHOTIC REACTIONS TO DAILY-LIFE STRESSORS?
  89. The intriguing relationship between coronary heart disease and mental disorders
  90. Sensitivity to Peer Evaluation and Its Genetic and Environmental Determinants: Findings from a Population-Based Twin Study
  91. Adherence to physical activity recommendations and physical and mental health risk in people with severe mental illness in Uganda
  92. Self-Reported Cognitive Biases Are Equally Present in Patients Diagnosed With Psychotic Versus Nonpsychotic Disorders
  93. Psychosis, Antipsychotic Medication, and Sexual Dysfunctions
  94. Validity and correlates of the International Physical Activity Questionnaire in first-episode psychosis
  95. Network Approach to Understanding Emotion Dynamics in Relation to Childhood Trauma and Genetic Liability to Psychopathology: Replication of a Prospective Experience Sampling Analysis
  96. The Bitter, Expensive Pill at the End of Life
  97. Interest, competence, appearance, fitness and social relatedness as motives for physical activity in Ugandan outpatients with psychosis
  98. Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis
  99. Is sensitivity to daily stress predictive of onset or persistence of psychopathology?
  100. White noise speech illusion and psychosis expression: An experimental investigation of psychosis liability
  101. Lower cardiorespiratory fitness is associated with more time spent sedentary in first episode psychosis: A pilot study
  102. Sedentary Behavior in People Living With HIV: A Systematic Review and Meta-Analysis
  103. Child Maltreatment and Clinical Outcome in Individuals at Ultra-High Risk for Psychosis in the EU-GEI High Risk Study
  104. Perceived Stress and Its Relationship With Chronic Medical Conditions and Multimorbidity Among 229,293 Community-Dwelling Adults in 44 Low- and Middle-Income Countries
  105. Psychological and Biological Validation of a Novel Digital Social Peer Evaluation Experiment (digi-SPEE)
  106. Physical health policies and metabolic screening in mental health care systems of sub-Saharan African countries: a systematic review
  107. Physical activity correlates in people living with HIV/AIDS: a systematic review of 45 studies
  108. Prescribing in schizophrenia and psychosis: Increasing polypharmacy over time
  109. The Relationship Between the Personality Inventory for the DSM-5 (PID-5) and the Psychotic Disorder in a Clinical Sample
  110. Reversing the downward spiral for people with severe mental illness through educational innovations
  111. A systematic review of physical activity policy recommendations and interventions for people with mental health problems in Sub-Saharan African countries
  112. Global physical activity levels among people living with HIV: a systematic review and meta-analysis
  113. Physical activity as a vital sign in patients with bipolar disorder
  114. The prevalence of diabetes mellitus type 2 in people with alcohol use disorders: a systematic review and large scale meta-analysis
  115. Dropout from physical activity interventions in people living with HIV: a systematic review and meta-analysis
  116. Membrane lipidomics in schizophrenia patients: a correlational study with clinical and cognitive manifestations
  117. Dropout from physical activity interventions in children and adolescents with attention deficit hyperactivity disorder: A systematic review and meta-analysis
  118. Changes in metabolic parameters in patients with severe mental illness over a 10-year period: A retrospective cohort study
  119. Is autonomous motivation the key to maintaining an active lifestyle in first-episode psychosis?
  120. Physical activity and sedentary behavior in people with bipolar disorder: A systematic review and meta-analysis
  121. The Functional Exercise Capacity Is Associated With Global Functioning in People With Bipolar Disorder
  122. BMI independently relates to glycaemia in patients with severe enduring mental illness (SMI)
  123. Impact of antipsychotic medication on physical activity and physical fitness in adolescents: An exploratory study
  124. Sitting time, physical fitness impairments and metabolic abnormalities in people with bipolar disorder: An exploratory study
  125. Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis
  126. Serious reportable events within the inpatient mental health care: Impact on physicians and nurses
  127. Cardiorespiratory fitness in outpatients with bipolar disorder versus matched controls: An exploratory study
  128. The Prevalence of Metabolic Syndrome in Alcohol Use Disorders: A Systematic Review and Meta-analysis
  129. Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders
  130. Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: a systematic review and large scale meta-analysis
  131. The prevalence and predictors of obstructive sleep apnea in major depressive disorder, bipolar disorder and schizophrenia: A systematic review and meta-analysis
  132. Depressive symptoms and muscular fitness contribute independently to the ability to perform daily life activities in people with bipolar disorder
  133. Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review
  134. DSM-5 section III personality traits and section II personality disorders in a Flemish community sample
  135. Genetic Evaluation of Schizophrenia Using the Illumina HumanExome Chip
  136. Concurrent validity of the international physical activity questionnaire in outpatients with bipolar disorder: Comparison with the Sensewear Armband
  137. Type 2 Diabetes Mellitus in Youth Exposed to Antipsychotics
  138. Physical activity as a vital sign in patients with schizophrenia: Evidence and clinical recommendations
  139. Knowledge of Psychiatric Nurses About the Potentially Lethal Side-Effects of Clozapine
  140. Bone mineral density, osteoporosis, and fractures among people with eating disorders: a systematic review and meta-analysis
  141. A comparison of physical fitness in patients with bipolar disorder, schizophrenia and healthy controls
  142. Type 2 Diabetes Mellitus
  143. Structural Brain Connectivity as a Genetic Marker for Schizophrenia
  144. Attitudes of Psychiatric Nurses about the Request for Euthanasia on the Basis of Unbearable Mental Suffering(UMS)
  145. Reply
  146. Validity of the 6min walk test in outpatients with bipolar disorder
  147. Do Advanced Statistical Techniques Really Help in the Diagnosis of the Metabolic Syndrome in Patients Treated With Second-Generation Antipsychotics?
  148. Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis
  149. The functional exercise capacity in patients with bipolar disorder versus healthy controls: A pilot study
  150. A Systematic Review of Physical Activity Correlates in Alcohol Use Disorders
  151. Test–retest reliability, feasibility and clinical correlates of the Eurofit test battery in people with bipolar disorder
  152. The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics
  153. Health-related quality of life and aerobic fitness in people with schizophrenia
  154. Emerging Drugs and Indications for Cardio-Metabolic Disorders in People with Severe Mental Illness
  155. Promotion of physical health in persons with schizophrenia: can we prevent cardiometabolic problems before they begin?
  156. Prevalence and Predictors of Type 2 Diabetes Mellitus in People With Bipolar Disorder
  157. Aerobic capacity is associated with global functioning in people with schizophrenia
  158. Absence ofN-Methyl-D-Aspartate Receptor IgG Autoantibodies in Schizophrenia
  159. Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review
  160. TYPE 2 DIABETES IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: A META-ANALYSIS OF PREVALENCE ESTIMATES AND PREDICTORS
  161. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder
  162. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management
  163. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis
  164. Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis
  165. Health-related physical fitness in patients with bipolar disorder vs. healthy controls: An exploratory study
  166. How can we promote smoking cessation in people with schizophrenia in practice? A clinical overview
  167. Promotion of cardiorespiratory fitness in schizophrenia: a clinical overview and meta-analysis
  168. The Construct Validity of the Dutch Personality Inventory for DSM-5 Personality Disorders (PID-5) in a Clinical Sample
  169. Schizophrenia and the risk of fractures: a systematic review and comparative meta-analysis
  170. Associations Between Metabolic and Aerobic Fitness Parameters in Patients With Schizophrenia
  171. Negative symptoms are associated with lower autonomous motivation towards physical activity in people with schizophrenia
  172. Associative stigma in family members of psychotic patients in Flanders: An exploratory study
  173. Do people with mental illness receive adequate smoking cessation advice? A systematic review and meta-analysis
  174. A Clinical Review of the Treatment of Catatonia
  175. Metabolic syndrome and lung function in schizophrenia: A pilot study
  176. The prevalence and moderators of clinical pain in people with schizophrenia: A systematic review and large scale meta-analysis
  177. Single-subject classification of schizophrenia patients based on a combination of oddball and mismatch evoked potential paradigms
  178. Reliability and clinical correlates of the Astrand–Rhyming sub-maximal exercise test in patients with schizophrenia or schizoaffective disorder
  179. Treatment Continuation and Treatment Characteristics of 3 Long Acting Antipsychotic Medications (Paliperidone Palmitate, Risperidone Microspheres and Haloperidol Decanoate) in Belgium
  180. Somatic Problems and Dual Disorder Patients
  181. Analysis of auto-antibodies in schizophrenia
  182. C.11.01 Metabolic effects in schizophrenia: perception versus reality
  183. Changes in physical activity, physical fitness, self-perception and quality of life following a 6-month physical activity counseling and cognitive behavioral therapy program in outpatients with binge eating disorder
  184. Analysis of pathogenic autoantibodies against the N-methyl-d-aspartate glutamate receptor in schizophrenia
  185. Self-determination and stage of readiness to change physical activity behaviour in schizophrenia
  186. The prevalence of pain in bipolar disorder: a systematic review and large-scale meta-analysis
  187. The functional exercise capacity and its correlates in obese treatment-seeking people with binge eating disorder: an exploratory study
  188. A meta-analysis of prevalence estimates and moderators of low bone mass in people with schizophrenia
  189. Variability in Working Memory Performance Explained by Epistasis vs Polygenic Scores in theZNF804APathway
  190. Severe mental illness: antipsychotics (revision number 8)
  191. In search of biomarkers for schizophrenia using electroencephalography
  192. Markers of inflammation in schizophrenia: association vs. causation
  193. Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations
  194. No association between genetic or epigenetic variation in insulin growth factors and antipsychotic-induced metabolic disturbances in a cross-sectional sample
  195. The Assessment, Benefits and Delivery of Physical Activity in People with Schizophrenia: A Survey of Members of the International Organization of Physical Therapists in Mental Health
  196. Second-generation and newly approved antipsychotics, serum prolactin levels and sexual dysfunctions: a critical literature review
  197. DYSGLYCEMIC SIGNALS IN CHILDREN AND ADOLESCENTS TREATED WITH ANTIPSYCHOTICS FOR THE FIRST TIME
  198. Poster #S175 THE ERYTHROCYTE MEMBRANE LIPID ABNORMALITIES OBSERVED IN SCHIZOPHRENIA PATIENTS SUPPORT THE OXIDATIVE STRESS HYPOTHESIS IN SCHIZOPHRENIA
  199. Poster #T176 THE INCREASED NUMBER OF PHOSPHOLIPID ABNORMALITIES OBSERVED IN THE ERYTHROCYTE MEMBRANE OF SCHIZOPHRENIA PATIENTS IS ASSOCIATED WITH INCREASED PSYCHOPATHOLOGY
  200. Health related quality of life, physical fitness and physical activity participation in treatment-seeking obese persons with and without binge eating disorder
  201. Registration of aggressive incidents in an adolescent forensic psychiatric unit and implications for further practice
  202. The Effects of Novel and Newly Approved Antipsychotics on Serum Prolactin Levels: A Comprehensive Review
  203. Associations between expiratory spirometry parameters and limitations in daily life activities in patients with schizophrenia
  204. Dysmetabolic features of the overweight patients receiving antipsychotic drugs: A comparison with normal weight and obese subjects
  205. The assessment of creativity in creativity/psychopathology research – a systematic review
  206. Diabetes Risk Potentially Underestimated in Youth and Children Receiving Antipsychotics
  207. Corrections
  208. EPA Guidance on Tobacco Dependence and Strategies for Smoking Cessation in People with Mental Illness
  209. Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci
  210. Neurobiological effects of physical exercise in schizophrenia: a systematic review
  211. Creativity and Psychopathology: A Systematic Review
  212. Preliminary study of associative stigma among trainee psychiatrists in Flanders, Belgium
  213. Associations between perceived neighbourhood environmental attributes and self-reported sitting time in patients with schizophrenia: A pilot study
  214. Physical activity and sedentary behaviour in outpatients with schizophrenia: A systematic review and meta-analysis
  215. The importance of self-determined motivation towards physical activity in patients with schizophrenia
  216. The one and the many: effects of the cell adhesion molecule pathway on neuropsychological function in psychosis
  217. Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables
  218. There is a need for physiotherapists in the multidisciplinary treatment of schizophrenia
  219. Stigmatization of schizophrenia in Flemish newspapers
  220. Associations between physical activity and the built environment in patients with schizophrenia: a multi-centre study
  221. P.1.j.025 Abnormal cognitive salience but not WCST scores are associated with poor outcome in patients with schizophrenia
  222. A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls
  223. End-of-Life (Care) Perspectives and Expectations of Patients With Schizophrenia
  224. Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia
  225. Physical Activity Correlates in Persons with Binge Eating Disorder: A Systematic Review
  226. Antipsychotics for acute schizophrenia: making choices
  227. Neurocognition in clinical high risk young adults who did or did not convert to a first schizophrenic psychosis: A meta-analysis
  228. Diabetes, physical activity participation and exercise capacity in patients with schizophrenia
  229. Response to Bartoli et al.
  230. A systematic review of physical therapy interventions for patients with anorexia and bulemia nervosa
  231. The Cognitive Biases Questionnaire for Psychosis (CBQ-P) and the Davos Assessment of Cognitive Biases (DACOBS): Validation in a Flemish sample of psychotic patients and healthy controls
  232. Frequency, Characteristics and Management of Adolescent Inpatient Aggression
  233. Investigation into the long-term metabolic effects of aripiprazole adjunctive to lithium, valproate, or lamotrigine
  234. Relationships between physical fitness, physical activity, smoking and metabolic and mental health parameters in people with schizophrenia
  235. All SNPs Are Not Created Equal: Genome-Wide Association Studies Reveal a Consistent Pattern of Enrichment among Functionally Annotated SNPs
  236. Screening for diabetes in severe mental illness (revision number 16)
  237. A systematic review on physical therapy interventions for patients with binge eating disorder
  238. CNR1 Gene and Risk of the Metabolic Syndrome in Patients With Schizophrenia
  239. SOCIAL ANXIETY IN PHYSICAL ACTIVITY PARTICIPATION IN PATIENTS WITH MENTAL ILLNESS: A CROSS-SECTIONAL MULTICENTER STUDY
  240. Genetic Schizophrenia Risk Variants Jointly Modulate Total Brain and White Matter Volume
  241. Metabolic Syndrome and Metabolic Abnormalities in Bipolar Disorder: A Meta-Analysis of Prevalence Rates and Moderators
  242. Prediabetic increase in hemoglobin A1c compared with impaired fasting glucose in patients receiving antipsychotic drugs
  243. Schizophrenia genetic variants are not associated with intelligence
  244. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review
  245. Insulin secretion in patients receiving clozapine, olanzapine, quetiapine and risperidone
  246. An impaired health related muscular fitness contributes to a reduced walking capacity in patients with schizophrenia: a cross-sectional study
  247. Genome-Wide Association Study of Clinical Dimensions of Schizophrenia: Polygenic Effect on Disorganized Symptoms
  248. Associations between sedentary behaviour and metabolic parameters in patients with schizophrenia
  249. Common variant at 16p11.2 conferring risk of psychosis
  250. Replication Study and Meta-Analysis in European Samples Supports Association of the 3p21.1 Locus with Bipolar Disorder
  251. Genetic association study of the P300 endophenotype in schizophrenia
  252. P.8.b.002 The Global Alliance of Mental Illness Advocacy Networks (GAMIAN-Europe) pan European adherence to treatment
  253. Creativity and Psychiatric Illness: The Search for a Missing Link - An Historical Context for Current Research
  254. Genetic Variation Underlying Psychosis-inducing Effects of Cannabis: Critical Review and Future Directions
  255. Body Weight and Metabolic Adverse Effects of Asenapine, Iloperidone, Lurasidone and Paliperidone in the Treatment of Schizophrenia and Bipolar Disorder
  256. Osteoporosis and fracture risk in people with schizophrenia
  257. Eurofit test battery in patients with schizophrenia or schizoaffective disorder: Reliability and clinical correlates
  258. Progressive muscle relaxation in persons with schizophrenia: a systematic review of randomized controlled trials
  259. Authors' reply
  260. Medical outcome of psychiatric inpatients with admission hyponatremia
  261. Safety and tolerability of antipsychotic polypharmacy
  262. Yoga in schizophrenia: a systematic review of randomised controlled trials
  263. SYSTEMATIC EVALUATION OF GUIDELINES FOR MONITORING CARDIO-METABOLIC RISK IN SCHIZOPHRENIA
  264. INTERNATIONAL ORGANIZATION OF PHYSICAL THERAPY IN MENTAL HEALTH-CONSENSUS ON PHYSICAL ACTIVITY WITHIN MULTIDISCIPLINARY REHABILITATION PROGRAMMES FOR MINIMISING CARDIO-METABOLIC RISK IN PATIENTS WITH SCHIZOPHRENIA
  265. Poster #99 CNR1 AND RISK OF THE METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA
  266. Poster #81 GENETIC VARIATION IN ABCB1 ASSOCIATED WITH P300 AMPLITUDE IN SCHIZOPHRENIA
  267. Expression QTL analysis of top loci from GWAS meta-analysis highlights additional schizophrenia candidate genes
  268. Parsing the components of the psychomotor syndrome in schizophrenia
  269. The functional exercise capacity is correlated with global functioning in patients with schizophrenia
  270. Differential effects of olanzapine and risperidone on plasma adiponectin levels over time: Results from a 3-month prospective open-label study
  271. Prevalence of Metabolic Syndrome and Metabolic Abnormalities in Schizophrenia and Related Disorders—A Systematic Review and Meta-Analysis
  272. Prediabetes in Patients Treated With Antipsychotic Drugs
  273. A systematic review of correlates of physical activity in patients with schizophrenia
  274. Metaphor interpretation and use: A window into semantics in schizophrenia
  275. Incident somatic comorbidity after psychosis: results from a retrospective cohort study based on Flemish general practice data
  276. Systematic Review of the Benefits of Physical Therapy Within a Multidisciplinary Care Approach for People With Schizophrenia
  277. Meta-analysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: Evidence for a common genetic vulnerability?
  278. The METEOR study
  279. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs
  280. Review: people with schizophrenia or other mental illnesses have a lower rate of invasive coronary interventions after acute coronary syndrome
  281. International Organization of Physical Therapy in Mental Health consensus on physical activity within multidisciplinary rehabilitation programmes for minimising cardio-metabolic risk in patients with schizophrenia
  282. Genome-wide association study identifies five new schizophrenia loci
  283. Endogenic and Iatrogenic Diabetes Mellitus in Drug-naïve Schizophrenia: The Role of Olanzapine and its Place in the Psychopharmacological Treatment Algorithm
  284. P.2.e.023 Long -term metabolic effects of aripiprazole adjunctive to lithium, valproate or lamotrigine
  285. Association of the metabolic syndrome with physical activity performance in patients with schizophrenia
  286. C.03.03 Improving patient outcomes: optimising efficacy and safety of antipsychotic treatment
  287. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices
  288. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation
  289. Common variants at VRK2 and TCF4 conferring risk of schizophrenia
  290. Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe
  291. Lack of physical activity during leisure time contributes to an impaired health related quality of life in patients with schizophrenia
  292. Knowledge about HIV in People with Schizophrenia: A General Population Comparison
  293. Efectos adversos metabólicos y endocrinos de los antipsicóticos de segunda generación en niños y adolescentes: una revisión sistemática de ensayos aleatorizados, controlados con placebo y guías de práctica clínica
  294. Quality Assessment of Physical Activity Recommendations Within Clinical Practice Guidelines for the Prevention and Treatment of Cardio-metabolic Risk Factors in People With Schizophrenia
  295. Smoking cessation for patients on clozapine
  296. Dual association of a TRKA polymorphism with schizophrenia
  297. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level
  298. Reliability, minimal detectable changes, practice effects and correlates of the 6-min walk test in patients with schizophrenia
  299. Physical activity participation, functional exercise capacity and self-esteem in patients with schizophrenia
  300. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice
  301. Ventajas y desventajas del tratamiento de combinación con antipsicóticos. Reunión ECNP Consensus, marzo de 2008, Niza
  302. Effects of progressive muscle relaxation on state anxiety and subjective well-being in people with schizophrenia: a randomized controlled trial
  303. Prevalence and severity of antipsychotic related constipation in patients with schizophrenia: a retrospective descriptive study
  304. Effects of cannabis use on age at onset in schizophrenia and bipolar disorder
  305. Age at onset of psychotic disorder: Cannabis, BDNF Val66Met, and sex-specific models of gene-environment interaction
  306. Prevalence and correlates of seclusion and restraint use in children and adolescents: a systematic review
  307. Clock genes and body composition in patients with schizophrenia under treatment with antipsychotic drugs
  308. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
  309. Relationships between obesity, functional exercise capacity, physical activity participation and physical self-perception in people with schizophrenia
  310. Second-generation antipsychotics and constipation: A review of the literature
  311. The METEOR study of diabetes and other metabolic disorders in patients with schizophrenia treated with antipsychotic drugs. I. Methodology
  312. A head-to-head comparison of sertindole and risperidone on metabolic parameters
  313. WITHDRAWN: Maladie cardiovasculaire et diabète chez les sujets souffrant d’une maladie mentale sévère. Déclaration de position de l’European Psychiatric Association (EPA), soutenue par l’European Association for the Study of Diabetes (EASD) et l’Europe...
  314. Editorial for Nordic Journal of Psychiatry
  315. Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone
  316. MTHFR genotype and differential evolution of metabolic parameters after initiation of a second generation antipsychotic: an observational study
  317. State anxiety, psychological stress and positive well-being responses to yoga and aerobic exercise in people with schizophrenia: a pilot study
  318. MTHFR and risk of metabolic syndrome in patients with schizophrenia
  319. No association between MTHFR C677T or A1298C and age at onset of schizophrenia
  320. The prevention of deep venous thrombosis in physically restrained patients with schizophrenia
  321. Management of physical health in patients with schizophrenia: practical recommendations
  322. Physical health management in psychiatric settings
  323. Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia
  324. MTHFR GENOTYPE AND DIFFERENTIAL EVOLUTION OF METABOLIC PARAMETERS AFTER INITIATION OF A SECOND GENERATION ANTIPSYCHOTIC
  325. VRINT: A NEWLY DEVELOPED EARLY PSYCHOSIS SERVICE IN BELGIUM
  326. AGE AT ONSET OF PSYCHOSIS IN PATIENTS WITH SCHIZOPHRENIA: EVIDENCE FOR A SEX-DEPENDENT INTERACTION BETWEEN BDNF VAL66MET GENOTYPE AND CANNABIS USE
  327. DO ANTIPSYCHOTIC MEDICATIONS REDUCE OR INCREASE MORTALITY IN SCHIZOPHRENIA? A CRITICAL APPRAISAL OF THE FIN-11 STUDY
  328. IN VIVO PET IMAGING OF CEREBRAL TYPE 1 CANNABINOID RECEPTOR AVAILABILITY IN PATIENTS WITH SCHIZOPHRENIA
  329. PREVALENCE AND SEVERITY OF ANTIPSYCHOTIC RELATED CONSTIPATION
  330. METABOLIC PARAMETERS IN A SUBSET OF PATIENTS IN THE SCOP STUDY
  331. O78 Effets contrastés de l’olanzapine et de la rispéridone sur les taux plasmatiques d’adiponectine chez les patients schizophrènes nouvellement traités
  332. Maladie cardiovasculaire et diabète chez les personnes atteintes d’une maladie mentale sévère
  333. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study
  334. Antipsychotic Use and Risk for Hyperglycemia in Elderly Patients With DM
  335. Cardiometabolic effects of physical activity interventions for people with schizophrenia
  336. Evaluation of the association between insight and symptoms in a large sample of patients with schizophrenia
  337. Mortality in patients with schizophrenia
  338. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (...
  339. Abnormal transbilayer distribution of phospholipids in red blood cell membranes in schizophrenia
  340. Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent?
  341. Advantages and disadvantages of combination treatment with antipsychotics
  342. The relation between neurocognitive dysfunction and impaired insight in patients with schizophrenia
  343. Prevalence of HIV and hepatitis C infection among patients with schizophrenia
  344. Metabolic syndrome in people with schizophrenia: a review
  345. Cardiovascular disease and diabetes in people with severe mental illness
  346. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder
  347. Traitements neuroleptiques et troubles métaboliques
  348. Psychiatric Diagnosis as an Independent Risk Factor for Metabolic Disturbances
  349. P.3.c.070 Metabolic disorders in patients with schizophrenia treated by antipsychotic drugs in Europe: the METEOR study
  350. P.3.c.071 Epidemiological study for the evaluation of metabolic disorders in patients with schizophrenia: The METEOR Study
  351. A roadmap to disentangle the molecular etiology of schizophrenia
  352. Incidence of schizophrenia lower in people with type I diabetes
  353. Comorbid Somatic Illnesses in Patients With Severe Mental Disorders
  354. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review
  355. Major Changes in Glucose Metabolism, Including New-Onset Diabetes, Within 3 Months After Initiation of or Switch to Atypical Antipsychotic Medication in Patients With Schizophrenia and Schizoaffective Disorder
  356. Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder
  357. Evidence that the COMTVal158Met polymorphism moderates sensitivity to stress in psychosis: An experience-sampling study
  358. P.2.f.004 Clinical and biological features associated with membrane phospholipid distribution in patient with bipolar disorder
  359. C.21.03 Management strategies for patients with a present or emerging health risk
  360. P.2.f.005 Membrane phospholipid distribution: a comparison between patient with schizophrenia and bipolar disorder
  361. Reply to Applicability of the Oral Glucose Tolerance Test in Assessing Prevalence and Incidence of Diabetes Mellitus in Schizophrenia
  362. The association between cognition and functional outcome in first-episode patients with schizophrenia: mystery resolved?
  363. Anticholinergic use in hospitalised schizophrenic patients in Belgium
  364. Abnormal glucose metabolism in patients treated with antipsychotics
  365. Metabolic control in patients with schizophrenia treated with amisulpride or olanzapine
  366. Remission criteria for schizophrenia: Evaluation in a large naturalistic cohort
  367. Troubles métaboliques associés aux antipsychotiques atypiques : consensus belge sur la conduite à tenir
  368. A Case Series: Evaluation of the Metabolic Safety of Aripiprazole
  369. Impact of antipsychotic treatment on physical health
  370. Preliminary results of the Belgian lifestyle program ENERGIE on weight in patients with psychiatric disorders
  371. Metabole stoornissen bij patiënten met schizofrenie behandeld met tweedegeneratieantipsychotica
  372. Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder
  373. Premorbid IQ as a predictor for the course of IQ in first onset patients with schizophrenia: A 10-year follow-up study
  374. Body weight and self-esteem in patients with schizophrenia evaluated with B-WISE®
  375. Letter to the Editor
  376. Screening for Diabetes and Other Metabolic Abnormalities in Patients With Schizophrenia and Schizoaffective Disorder
  377. Reversibility of Antipsychotic Treatment–Related Diabetes in Patients With Schizophrenia
  378. The five-factor model of the Positive and Negative Syndrome Scale I: Confirmatory factor analysis fails to confirm 25 published five-factor solutions
  379. The five-factor model of the Positive and Negative Syndrome Scale II: A ten-fold cross-validation of a revised model
  380. Usefulness of glycosylated haemoglobin (HbA1c) to screen for diabetes in patients with schizophrenia
  381. Stereotypy in schizophrenia
  382. Oral glucose tolerance tests in treated patients with schizophrenia.
  383. Schizophrenia: who is at risk? Who is a case?
  384. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication
  385. P.3.d.003 A cross-sectional study of adiponectin in patients with schizophrenia
  386. P.3.c.005 Evaluation of the metabolic safety of aripiprazole
  387. P.3.c.004 Screening for metabolic abnormalities in patients with schizophrenia treated with antipsychotics: are we doing enough?
  388. Pharmacological treatment of hospitalised schizophrenic patients in Belgium
  389. GLUCOSE ABNORMALITIES IN A NON-PSYCHOTIC PATIENT TREATED WITH RISPERIDONE
  390. Belgian consensus on metabolic problems associated with atypical antipsychotics
  391. A study of the family burden of 150 family members of schizophrenic patients
  392. PMH45 MAPPING UTILITY SCORES FROM THE EQ-5D AND SF-6D ONTO THE SCHIZOPHRENIA QUALITY OF LIFE SCALE
  393. Expressed Emotion in the Client-Professional Dyad
  394. The Generic Alternative in Schizophrenia
  395. Psychotic disorders in Prader-Willi syndrome
  396. Risque de diabète sucré sous antipsychotiques atypiques
  397. Safe ECT in a Patient With the Ehlers–Danlos Syndrome
  398. P.2.056 Sound and vision, using popular media to improve knowledge about schizophrenia
  399. P.2.054 Adherence to antipsychotic dosing guidelines in the treatment of hospitalised psychotic patients in Belgium
  400. P.2.055 The influence of antipsychotic drug treatment on anticholinergic use and complexity of medication schemes in hospitalised pschotic patient in Belgium
  401. Guidelines adherence in treated schizophrenic patients
  402. Sound and vision, using popular media to improve knowledge about schizophrenia
  403. Expressed emotion in the client-professional caregiver dyad: are symptoms, coping strategies and personality related?
  404. Expressed emotion
  405. Validation study of PECC (Psychosis Evaluation tool for Common use by Caregivers): Interscale validity and inter-rater reliability
  406. Expressed emotion in staff-patient relationships: the professionals' and residents' perspectives
  407. The Care Perception Questionnaire
  408. Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study
  409. The clinical value of risperidone and olanzapine: A meta-analysis of efficacy and safety
  410. Can we identify the factors influencing the burden on family members of patients with schizophrenia?
  411. Hospitalised schizophrenic patients in Belgium, demographic and clinical data
  412. Interscale validity of PECC, a psychosis evaluation tool for common use by caregivers
  413. Failure to establish linkage on the X chromosome in 301 families with schizophrenia or schizoaffective disorder
  414. Animal models of schizophrenia
  415. A 1-Year Cost-Effectiveness Model for the Treatment of Chronic Schizophrenia with Acute Exacerbations in Belgium
  416. Trail making data in schizophrenic patients
  417. Expressed emotion of professional caregivers of patients with schizophrenia. An exploration of the field
  418. Family stigma: A study of relatives of schizophrenic patients
  419. Intelligence data in first episode psychotic patients 10 years after hospital discharge
  420. Knowledge about schizophrenia in basic caregivers in Belgium
  421. Life chart data in first episode psychotic patients 10 years after hospital discharge
  422. Medication use in hospitalised schizophrenic patients in Belgium
  423. Suïcide en schizofrenie
  424. A genome-wide search for schizophrenia susceptibility genes
  425. Sexual dysfunction: The unspoken side effect of antipsychotics
  426. First-episode schizophrenia, a naturalistic 10 year follow-up study
  427. Introduction of clozapine in Belgium
  428. Health Care Expenditure on Schizophrenia Patients in Belgium
  429. High prevalence of Helicobacter pylori in institutionalized schizophrenic patients
  430. Rehabilitation and Resocialization for the Long-Term Mentally III in Belgium: Description of Services and History of Their Development
  431. High prevalence of helicobacfer pylori in schizophrenic patients
  432. No evidence for more auto-immune pathology in first degree relatives of schizophrenic patients
  433. PQCSPI, an instrument to measure the perception of quality of care for psychotic inpatients
  434. Suicide in Young Schizophrenic Patients During and After Inpatient Treatment
  435. Partial hospitalization at night: the Brussels Nighthospital
  436. Lujan-Fryns syndrome in the differential diagnosis of schizophrenia
  437. Psychotherapy with “New Chronic” Psychotic Patients
  438. The Brussels Night Hospital: A Three-year Follow-up Study
  439. Development of an instrument to measure consumers perception of quality of care for psychotic inpatients
  440. Study of the possible association of HLA class II, CD4, and CD3 polymorphisms with schizophrenia
  441. Treatment of the neuroleptic malignant syndrome with ECT
  442. The function of the brussels night hospital: Dumping, recycling or container?
  443. Management of lethal catatonia with dantrolene sodium
  444. Psychiatric Aspects of Suicidal Behaviour: Schizophrenia